Meet Our Featured Speakers

Gain two days of insight, connection, and intelligence across the radiopharmaceutical value chain, covering isotope supply, clinical trials, patient safety, manufacturing capacity, and reimbursement strategy.

Benefits of attending include:

• Benchmark clinical trials strategy for radioligand and theranostic therapies, from dosimetry and toxicity design through long-term safety data at every stage of development.
• Assess the safety profile of in-trial and preclinical radionuclides, including alpha-emitter toxicity data shaping regulatory pathways and patient risk management.
• Meet the talent pool behind radiochemistry, hot-cell manufacturing, and nuclear medicine, and identify your next hire, technical lead, or research partner.
• Gain firsthand insights into the bottlenecks limiting isotope supply, manufacturing capacity, and reimbursement, and the organizations positioned to resolve them.
• Connect with isotope producers, CDMOs, nuclear medicine leaders, and investors to find your next manufacturing, licensing, or investment partner.

• Understand how cross-sector acquisitions, capital, and partnering are reshaping radiopharmaceutical commercial strategy and where investment is heading next
• Assess alpha-emitter platforms, including actinium-225 and lead-212, alongside established lutetium-177 therapy and theranostic pairing strategies
• Evaluate isotope supply security, domestic molybdenum-99 sourcing, and the production routes that keep radioligand therapy programs on schedule
• Benchmark good manufacturing practice, or GMP, scale-up, hot-cell capacity, automation, and workforce planning across the CDMO and pharmaceutical base
• Navigate dual FDA and NRC oversight, dosimetry expectations, licensing reform, and reimbursement changes shaping commercial delivery to treatment sites